Product Information
CREXONT ER 52.5 MG-210 MG CAP is a brand product labeled by Amneal Pharmaceuticals LLC, priced at $4.5824 per EA under NDC 64896096816. Its NADAC has been published 79 times since Feb 19, 2025.
FDA first approved this application on Aug 7, 2024.
The High Outlier badge above means this manufacturer's average price in the carbidopa and levodopa market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
52.5; 210 mg/1; mg/1
Manufacturer
Amneal Pharmaceuticals LLCNDC
64896096816
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
7/1/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
New Drug (NDA)
FDA Application
NDA217186FDA Approved
8/7/2024
On Market Since
8/9/2024
Pharmacological Classes
Price Statistics
The NADAC for CREXONT ER 52.5 MG-210 MG CAP has been published 79 times since Feb 19, 2025, and over the history we have for it it has risen 9.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.5824 per EA |
|---|---|
| All-time high | $4.5824 (Aug 19, 2026) |
| All-time low | $4.1490 (Jun 18, 2025) |
| 52-week high | $4.5824 |
| 52-week low | $4.3564 |
| Median price | $4.3604 |
| Average price | $4.3297 |
| Largest weekly change | +5.0% (Jul 8, 2026) |
| Weeks tracked | 79 |
| Tracking since | Feb 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the carbidopa and levodopa market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CREXONT ER 52.5 MG-210 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for CREXONT ER 52.5 MG-210 MG CAP, manufactured by Amneal Pharmaceuticals LLC, is $4.5824 per EA (NDC 64896096816), effective Aug 19, 2026.
How has the price of CREXONT ER 52.5 MG-210 MG CAP changed over time?
Over the history we have for it, the NADAC for CREXONT ER 52.5 MG-210 MG CAP has risen 9.7%. It has been tracked across 79 weekly CMS publications since Feb 19, 2025.
What are the highest and lowest recorded NADAC prices for CREXONT ER 52.5 MG-210 MG CAP?
Since Feb 19, 2025, the NADAC for CREXONT ER 52.5 MG-210 MG CAP has ranged from a low of $4.1490 (Jun 18, 2025) to a high of $4.5824 (Aug 19, 2026), with a median of $4.3604 per EA.
Are there cheaper alternatives to CREXONT ER 52.5 MG-210 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of CREXONT ER 52.5 MG-210 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CREXONT ER 52.5 MG-210 MG CAP?
CREXONT ER 52.5 MG-210 MG CAP (NDC 64896096816) is labeled by Amneal Pharmaceuticals LLC, and CMS classifies it as a brand product.